Maravai LifeSciences Holdings, Inc.

NasdaqGS:MRVI Lagerbericht

Marktkapitalisierung: US$1.8b

Maravai LifeSciences Holdings Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Maravai LifeSciences Holdings hat ein Gesamteigenkapital von $777.4M und eine Gesamtverschuldung von $523.3M, was einen Verschuldungsgrad von 67.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $1.4B bzw. $667.3M.

Wichtige Informationen

67.3%

Verhältnis von Schulden zu Eigenkapital

US$523.33m

Verschuldung

Zinsdeckungsgradn/a
BargeldUS$561.69m
EigenkapitalUS$777.39m
GesamtverbindlichkeitenUS$667.25m
GesamtvermögenUS$1.44b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One

Jun 12

Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

May 14
Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%

An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Apr 07
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Feb 28
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Dec 19
Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price

Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Aug 14
Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates

Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Feb 28
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 01
Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

Maravai Lifesciences temporarily reinstates Carl Hull as CEO

Oct 19

Maravai LifeSciences appoints former Danaher executive as CEO

Oct 03

Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M

Aug 04

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jun 27
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 29
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price

Maravai Faces Skeptical Investors As Pandemic Enters New Period

Jan 27

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Dec 02
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk

Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Oct 07
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: MRVIDie kurzfristigen Aktiva des Unternehmens ($667.9M) übersteigen seine kurzfristigen Passiva ($59.0M).

Langfristige Verbindlichkeiten: MRVIDie kurzfristigen Vermögenswerte des Unternehmens ($667.9M) übersteigen seine langfristigen Verbindlichkeiten ($608.2M).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: MRVI über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: MRVI Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 229.6% auf 67.3% zurückgegangen.

Schuldendeckung: MRVIDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (6.2%) gedeckt.

Zinsdeckung: Es liegen nicht genügend Daten vor, um festzustellen, ob die Zinszahlungen von MRVI auf seine Schulden durch EBIT gut gedeckt sind.


Bilanz


Entdecken Sie finanziell stabile Unternehmen